Abstract
According to Pelis (1), “Blood is one of man's most compelling and omnipresent symbols. It signifies the opposition between life and death, health and sickness, power and powerlessness.” Blood and RBC transfusion, even done autologously, is a well proven treatment that, like the administration of aspirin, had never undergone the kind of rigorous, controlled clinical trials now required by the U.S. Food and Drug Administration. In a recent issue of PNAS, two papers (2, 3) provide new insights into the detrimental effects of storage on human RBCs. Some of the properties of stored blood have long been known to be problematic in the realm of blood transfusions. For example, we know that the oxygen affinity of stored blood rises during the storage period (4) and that intracellular allosteric regulators, notably 2,3-bisphosphoglyceric acid (DPG) and ATP, are depleted during storage. During the Vietnam era, U.S. Navy physician C. Robert Valeri and N. M. Hirsch (5) showed that “spiking”-stored RBCs with DPG and ATP precursors led to significant improvements in cardiovascular function. These findings prompted a significant effort in the following decade that was aimed at changing the oxygen affinity of RBCs with the goal of increasing the efficacy conveyed by transfusion of stored blood. From 1975 to 1980, I worked as an American Heart Established Investigator with the goal of tailor-making transfusion blood with specific oxygen-binding properties. Other scientists went as far as to fuse RBCs with phospholipid vesicles, or reversibly hemolyze RBCs, filling them with Hb and inositol hexaphosphate, a powerful nonmammalian heterotropic effector (6). In 1987, our understanding of the pathways of vascular regulation in human physiology took a surprising turn. Independent studies completed by Ignarro et al. (7) and Furchgott and Zawadzki (8) suggested endothelium-derived …
Keywords

This publication has 13 references indexed in Scilit: